Methods and compositions for normalizing the skin microbiome for sensitive skin
By encapsulating frankincense acid and its derivatives in nanoemulsions, the problem of instability is solved, stability and effectiveness in sensitive skin treatment is achieved, and skin barrier function and microbiome balance are improved.
Patent Information
- Application Number
- CN202080105013.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-18
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-11-18
AI Technical Summary
Frankincense acid and its derivatives are chemically unstable, resulting in discoloration and degradation in long-term storage and industrial applications, limiting its use in the field of fast-moving consumer goods.
Frankincense acid and its derivatives are encapsulated in a nanoemulsion with a liquid lipid core and a negative surface charge to form a stable external composition to improve its stability and application.
Through nano-encapsulation technology, the stability of frankincense acid and its derivatives is significantly improved, the skin barrier function is improved, nerve sensitivity is calmed, and the skin microbiome of sensitive skin is restored to a healthy state, effectively alleviating the subsubs of sensitive skin Clinical symptoms.
Smart Images

Figure CN116234554B_ABST
Abstract
Description
Field of the Invention
[0001] The present invention relates to the use of an external composition for improving subclinical symptoms of sensitive skin and normalizing the skin microbiome profile. More particularly, the composition comprises boswellic acid and / or its derivatives in a stable and encapsulated form, which are obtained from or contained in an extract of Boswellia serrata. The present invention also provides a method for improving the skin condition of people with sensitive skin. Background Art
[0002] Sensitive skin is a condition of the skin that is overly reactive to environmental factors and exaggerated skin reactions (such as stinging, itching, burning, erythema, and dryness) that can be triggered by contact with allergens such as cosmetic ingredients or extreme climatic conditions. The pathophysiology of sensitive skin is well-established and is characterized by impaired skin barrier function associated with a thin permeable stratum corneum and hypersensitivity to the nerve fibers innervating the epidermis. Impairment of the skin barrier and increased nerve sensitivity make sensitive skin more susceptible to chemical irritation and allergic reactions compared to healthy skin (Berardesca et al., 2013.).
[0003] Several studies have shown that skin microbiome dysbiosis is associated with skin diseases including psoriasis and atopic dermatitis (Alekseyenko et al., 2013, Byrd et al., 2017, and William & Gallo, 2015). Givaudan demonstrated a significant increase in pathogenic strains in a Caucasian population with sensitive skin, including Corynebacterium, Chryseobacterium, Snodgrassella, Kocuria, Micrococcus, and Lawsonella (Jarri et al., 2020). In addition, the composition of the skin microbiome in a Japanese population was shown to have a potential impact on the occurrence of skin allergies (Shinohara & Masaki, 2019). Therefore, maintaining or restoring the balance of the skin microbiome is crucial for overall skin health to avoid the occurrence of sensitive skin.
[0004] For centuries, extracts of gum resin from Boswellia serrata have been used in traditional folk medicine to treat various chronic inflammatory diseases. Boswellia serrata consists of four major pentacyclic triterpenoid acids, namely boswellic acid derivatives, including but not limited to β-boswellic acid (BBA), acetyl-β-boswellic acid (ABA), 11-keto-β-boswellic acid (KBBA), and acetyl-11-keto-β-boswellic acid (AKBA). These active compounds are responsible for inhibiting lipoxygenase-5 (LOX-5), a pro-inflammatory enzyme (MZ Siddiqui, 2010) and have been used as an oral supplement to treat chronic inflammatory diseases (US20190175678A1) and photoaged skin (Calzavara-Pintone et al., 2010). In addition, extracts of Boswellia serrata have been used in topical preparations to treat eczema symptoms in patients with psoriasis (Togni et al., 2014). Furthermore, specific active compounds such as AKBA have been shown to exhibit potent antibacterial and antibiofilm activities by disrupting the membrane integrity of Staphylococcus aureus and Staphylococcus epidermidis, revealing its potential application in the treatment of S. aureus infections (Raja et al., 2011).
[0005] There is a need for a composition that can treat subclinical symptoms of sensitive skin, thereby restoring sensitive skin to healthy skin. However, boswellic acid and its derivatives are chemically unstable and thus prone to discoloration and degradation upon long-term storage, which limits their industrial applicability in the field of fast moving consumer goods (FMCG) where a defined shelf life of the product is required. Therefore, there is a need for a stable composition comprising boswellic acid and / or its derivatives.
[0006] The present invention is based, at least in part, on the discovery of a composition comprising boswellic acid and / or its derivatives in a stable form and which can improve skin barrier function, calm neurosensitivity, and restore the skin microbiome of sensitive skin to that found in healthy skin. SUMMARY OF THE INVENTION
[0008] In one aspect, the present invention provides a topical composition comprising boswellic acid, one or more boswellic acid derivatives or a mixture thereof, wherein the boswellic acid, one or more boswellic acid derivatives or a mixture thereof are stabilized by encapsulation in a nanoemulsion having a liquid lipid core and a negative surface charge.
[0009] In another aspect of the present invention, there is provided a composition according to the present invention for alleviating subclinical symptoms of sensitive skin in a subject.
[0010] In another aspect of the invention, there is provided a composition according to the invention for normalizing the skin microbiome profile of a subject with sensitive skin.
[0011] In another aspect of the present invention, there is provided a composition of the present invention for use in a subject with healthy skin without causing disruption to the skin microbiome profile.
[0012] In another aspect of the present invention, there is provided a method of treating subclinical symptoms of sensitive skin in a subject, comprising applying to the skin of the subject a composition of the present invention.
[0013] In another aspect of the present invention, there is provided use of the composition of the present invention in the production of a medicament for treating subclinical symptoms of sensitive skin.
[0014] In yet another aspect, a composition according to the invention is provided for use in treating or preventing acne skin or acne-prone skin, oily skin, oily scalp, dry skin, dry scalp, irritated skin, irritated scalp, hair loss, graying of hair, aging skin, aging scalp, pigmented skin, dandruff, atopic dermatitis or seborrheic dermatitis.
[0015] In another aspect of the present invention, there is provided a method of treating or preventing acne skin or acne-prone skin, oily skin, oily scalp, dry skin, dry scalp, irritated skin, irritated scalp, aged skin, aged scalp, hair loss, graying hair, pigmented skin, dandruff, atopic dermatitis or seborrheic dermatitis, comprising applying a composition of the present invention to the skin of a subject.
[0016] In another aspect of the present invention, there is provided the use of a composition of the present invention in the manufacture of a medicament for treating or preventing acne skin or acne-prone skin, oily skin, oily scalp, dry skin, dry scalp, irritated skin, irritated scalp, aged skin, aged scalp, hair loss, graying of hair, pigmented skin, dandruff, atopic dermatitis or seborrheic dermatitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 provides a graphic representation of the different skin microbiome profiles of healthy skin and sensitive skin at the phylum level (A) and species level (B). *p < 0.05 indicates statistically significant differences between groups according to the Wilcoson paired signed-rank test.
[0019] Figure 2 A cartoon illustration of nanoencapsulated boswellic acid derivatives is provided, wherein the size of the nanoemulsion is in the range of 60-180 nm and the surface charge of the nanoemulsion is -65 to -75 mV.
[0020] Figure 3A graphical representation of the effect of topical application of Formulation 1 on skin nerve sensitivity based on the visual analogue score (VAS) of the lactic acid stimulation test (LAST) and improvement of skin barrier function based on transepidermal water loss (TEWL) measurement (A) (B) is provided. All values are presented as mean ± SEM of panelists (n = 12). *p < 0.05 is considered statistically significant between groups according to the Wilcoson paired signed rank test.
[0021] Figure 4 A graphical representation of the effect of topical application of Formulation 1 on the skin microbiome profile, including the abundance of bacteria belonging to the phylum Firmicutes and Staphylococcus epidermidis, is provided. All values are presented as the median of the panelists (n=12). *p<0.05 indicates statistically significant differences between groups according to the Wilcoson paired signed rank test.
[0022] Detailed description of the invention / embodiment
[0023] definition
[0024] It should be understood that the present invention is not limited to any particular method or scheme described herein. In addition, unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. It should also be understood that the terms used herein are only used to describe specific embodiments, and are not intended to limit the scope of the present invention, which will only be limited by the claims.
[0025] In this specification, unless the context requires otherwise due to explicit language or necessary implication, the word "comprise" or other grammatical variations such as "contain" or "include" are used in an inclusive sense, i.e., specifying the presence of the features described, but not excluding the presence or addition of further features in various embodiments of the invention. In other words, the listed steps or options do not need to be exhaustive.
[0026] It should be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms part of the common general knowledge in the art in Malaysia or any other country.
[0027] Unless otherwise indicated, the present invention employs conventional techniques of chemistry, molecular biology and microbiology, which are within the capabilities of those skilled in the art and are well known to the skilled artisan and fully explained in the literature.
[0028] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a vector" may include a plurality of vectors and reference to "a subject" may be a reference to one or more subjects, and so forth.
[0029] The term "(s)" following a noun refers to the singular or the plural, or both. The term "and / or" can mean "and" or "or."
[0030] Unless the context requires otherwise, all percentages mentioned herein are by weight of the composition.
[0031] Various features of the present invention are described and / or claimed with reference to a certain value or range of values. These values are intended to be related to the results of various appropriate measurement techniques and should therefore be interpreted as including the margin of error inherent in any particular measurement technique. Some of the values mentioned herein are represented by the term "about" to at least partially account for this variability. The term "about", when used to describe a value, preferably refers to an amount within ±25%, ±10%, ±5%, ±1% or ±0.1% of the value.
[0032] When a numerical range is expressed, it is expressly understood that this range includes the upper and lower limits of the stated range, and all values between these limits.
[0033] Composition
[0034] In a first aspect of the present invention, there is provided a topical composition comprising boswellic acid, one or more boswellic acid derivatives or a mixture thereof, wherein the boswellic acid, one or more boswellic acid derivatives and / or a mixture thereof are encapsulated in a nanoemulsion having a liquid lipid core and a negative surface charge.
[0035] In some embodiments, the boswellic acid or one or more derivatives thereof are substantially pure. In other embodiments, the boswellic acid or one or more derivatives thereof are present in a natural extract, including but not limited to Boswellia serrata extract, Boswellia sacra extract, Boswellia papyrifera extract, Boswellia frereana extract, and Boswellia carterii extract.
[0036] Boswellic acid has the structure given below:
[0037]
[0038] Boswellic acid or its derivatives are present in a variety of plant products, for example, boswellic acid and / or its derivatives can be extracted from Boswellia serrata or Boswellia carterii. Commercial sources can be obtained, for example, from Active International LLC (trade name: Viapure Boswellia), Sophartops (trade name: Sohartops Boswellin), Sabinsa (trade name: Boswellin CG), Ambe Phytoextracts (trade name: AKBA ultra), USA. Alternatively, extracts containing boswellic acid and / or its derivatives that can be used in the composition of the present invention can be obtained, for example, by any known extraction method by a person skilled in the art of phytochemistry. As used herein, "extract" refers to a substance made by extracting a raw material such as a part of a plant. Those skilled in the art will appreciate that there are many other extraction methods, including those known in the art and described in various patents and publications, that can be used to obtain extracts for practicing the present invention. For example, the extraction methods described in the following references can be used to implement the present invention, which are incorporated herein by reference: SS Niphadkar et al., Extraction of 3-O-acetyl-11-keto-β-boswellic acid (AKBA) from Boswellia serrataplant oleo gum resin using novel three phase partitioning (TPP) technique, 2017, J. Appl. Res. Med. Aromat. Plants, (7): 41-47; P. Shah et al., An improved process for preparation and purification of boswellic acids, WO2014195976A2, 2014; D Kumar et al., Boswellic acid–Potential tumour suppressant terpenoid–Photochemistry, Extraction and Isolation Methods-A comprehensive review study, J. Pharmacogn. Phytochem. 2016; 5 (3): 231-239.
[0039] The boswellic acid derivatives covered by the present invention include, but are not limited to, triterpene acids, such as α-boswellic acid, acetyl-α-boswellic acid, β-boswellic acid (BBA), acetyl-β-boswellic acid (ABA), 9,11-dehydro-α-boswellic acid, acetyl-9,11-dehydro-α-boswellic acid, 9,11-dehydro-β-boswellic acid, acetyl-9,11-dehydro-β-boswellic acid, lupeolic acid, acetyl-lupeolic acid, 11-keto-β-boswellic acid (KBBA), and 3-O-acetyl-11-keto-β-boswellic acid (AKBA). The boswellic acid derivatives encompassed by the present invention may further include, but are not limited to, derivatives of boswellic acid in which one or more hydrogen atoms are substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, halogen, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, aryloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, amino, alkylamino, dialkylamino , alkenylamino, alkynylamino, arylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, arylphenyloxy, heterocyclic group, heterocyclicoxy, heterocyclicamino, halogenated heterocyclic group, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxycarbonyl (carboaryloxy), sulfhydryl, alkylthio, benzylthio, acylthio and phosphorus-containing groups, as well as heterocyclic derivatives of boswellic acid.
[0040] In a specific embodiment, the composition comprises AKBA.
[0041] In some embodiments, the boswellic acids and / or derivatives thereof may be used in a "substantially pure form". This means that the boswellic acids or derivatives thereof are used in a form that is substantially free of other major components of the plant from which they are obtained, such as Boswellia serrata. In this context, substantially means that the boswellic acids and / or derivatives thereof used in the composition may contain one or more boswellic acids and / or derivatives thereof, but contain no more than 20% w / w of components other than boswellic acids and / or derivatives of the plant, or no more than 15% w / w, no more than 10% w / w, or no more than 5% w / w of other major components of the plant. In some embodiments, substantially pure form means that the boswellic acid and / or its derivatives composition contains at least 80% w / w boswellic acid and / or its derivatives, at least 85% w / w boswellic acid and / or its derivatives, at least 90% w / w boswellic acid and / or its derivatives, at least 95% w / w boswellic acid and / or its derivatives, at least 96% w / w boswellic acid and / or its derivatives, at least 97% w / w boswellic acid and / or its derivatives, at least 98% w / w boswellic acid and / or its derivatives, at least 99% w / w boswellic acid and / or its derivatives, at least 100% w / w boswellic acid and / or its derivatives. Thus, the composition may include pure boswellic acid and / or its derivatives, as well as extracts that retain a small amount of impurities from the plant from which it is obtained, such as Boswellia serrata.
[0042] In other embodiments, the boswellic acids and / or derivatives thereof are in the form of a plant extract. In these embodiments, the extract comprises at least 30%, particularly at least 40%, more particularly 50% of boswellic acids and / or derivatives thereof. For example, the extract may comprise 30-85%, 35-80%, 40-75%, 45-70% or 50-65% boswellic acids and / or derivatives thereof.
[0043] In other embodiments, the boswellic acids or their derivatives may be produced synthetically (Shamraiz et al., 2018), in which case any non-boswellic acid components would not be expected to be present in the plant extract.
[0044] In some embodiments, the boswellic acid derivative is AKBA in substantially pure form. In other embodiments, the boswellic acid and / or its derivative comprises AKBA. In other embodiments, the boswellic acid and / or its derivative is in the form of an extract, particularly a Boswellia serrata extract.
[0045] In some embodiments, the composition comprises boswellic acid and / or its derivatives in an amount ranging from 0.0001%-2.0%, particularly 0.0005%-1.0%, more particularly 0.001%-0.50%, most particularly 0.010%-0.10% by weight of the composition.
[0046] In some embodiments, the composition comprises AKBA in an amount of 0.0001% to 0.5%, particularly 0.001% to 0.1%, more particularly 0.01% to 0.05% by weight of the composition.
[0047] Boswellic acid, derivatives of boswellic acid or mixtures thereof are encapsulated in a nanoemulsion having a liquid lipid core and a negative surface charge. The boswellic acid and / or its derivatives are hydrophobic and in oil form. In some embodiments, the oil is a neat extract comprising boswellic acid and / or its derivatives. In other embodiments, the boswellic acid and / or its derivatives are dissolved in an oil / emollient, preferably an ester oil, without recrystallization. Any ester oil / emollient suitable for use in a pharmaceutical composition for skin surface application can be used, including but not limited to caprylic / capric triglyceride, coconut oil alcohol-caprylate, coconut oil alcohol-caprylate / caprate, dicaprylyl carbonate or any combination thereof.
[0048] In some embodiments, other encapsulation technologies may be used to protect and enhance transdermal delivery of boswellic acid and / or its derivatives, including but not limited to liposomes, neoribosomes, or phytosomes.
[0049] The boswellic acid and / or its derivatives are encapsulated in an encapsulating material comprising at least one emulsifier and a stabilizer. In some embodiments, the encapsulating material comprises an emulsifier and a co-emulsifier. In some embodiments, the emulsifier is selected from the glycerides of different fatty chains, including but not limited to citric acid glyceride, lactic acid glyceride, myristic acid glyceride, lauric acid glyceride, linoleic acid glyceride, oleic acid glyceride or any combination thereof or any fatty acid including a mixed glyceride of citric acid, lactic acid, myristic acid, lauric acid, linoleic acid and / or oleic acid. In one embodiment, the emulsifier is citric acid / lactic acid / linoleic acid / oleic acid glyceride (a mixed ester of citric acid, lactic acid, linoleic acid and oleic acid with glycerol). In some embodiments, the co-emulsifier is di- or polyglycerol ester, selected from but not limited to diglycerol monooleate, polyglycerol monooleate, polyglycerol monolinoleate or any combination thereof. In a specific embodiment, the co-emulsifier is diglycerol monooleate.
[0050] In some embodiments, the stabilizer can be selected from any kind of organic substance that can dissolve the emulsifier. Suitable examples are selected from alcohols or glycols, including but not limited to ethanol, isopropanol, propylene glycol, pentylene glycol, caprylyl glycol, especially pentylene glycol.
[0051] In some embodiments, the encapsulated boswellic acid and / or its derivatives comprise one or more emollients. In some embodiments, the emollient is C 12-15In some embodiments, the emollient is present in the lipid core. In other embodiments, the emollient is present in the encapsulating material. In other embodiments, the emollient is present in both the lipid core and the encapsulating material.
[0052] The pharmaceutical or cosmetic composition is formulated as an external composition suitable for topical application to the skin.
[0053] In some embodiments, the composition comprises a pharmaceutically or cosmetically acceptable carrier. The pharmaceutically or cosmetically acceptable carrier can be any pharmaceutically or cosmetically acceptable carrier, including pharmaceutically and / or dermatologically acceptable carriers, including surfactants. Pharmaceutically and / or dermatologically acceptable carriers are preferably compatible with skin, nails, mucous membranes, tissues and / or hair, and may include any conventionally used pharmaceutical or dermatological carriers that meet these requirements. Those skilled in the art can easily select such carriers. Carriers include, but are not limited to, emollients, emulsifiers and rheology modifiers.
[0054] Emollients suitable for use as carriers or vehicles for the compositions of the present invention include, for example, C 12-15 Alkyl benzoate, PPG-3 myristic ether, liquid paraffin and dimethicone. Emulsifiers suitable for use in the vehicle or carrier of the composition of the present invention include, for example, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, Ceteareth-20 (cetostearyl alcohol, which is a polyethylene glycol ether of cetyl alcohol). Rheology modifiers suitable for use in the vehicle or carrier of the composition of the present invention include, for example, carbomer, polyglyceryl acrylate and acrylate / C 10-30 Alkyl acrylate crosspolymer. Other suitable carriers include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene and / or polyoxypropylene compounds, emulsifying wax, sorbitan monostearate, polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), cetyl esters wax, cetyl alcohol, 2-octyl dodecanol, benzyl alcohol, sodium hyaluronate, hyaluronic acid and water.
[0055] The composition of the present invention may also include other suitable ingredients, including thickeners, fragrances, pearlescent agents, preservatives (e.g., ethylhexylglycerin, phenoxyethanol or hydroxyacetophenone), sunscreens, vitamins, silicones, gelling agents (e.g., hydrophilic or lipophilic gelling agents), antioxidants, solvents, fillers, odor absorbers, colorants, pH adjusters (e.g., sodium hydroxide), solubilizers (e.g., methylpropanediol), sunscreens, skin whitening agents, skin tanning agents, perfumes, sunscreens and preservatives. These ingredients may account for 0-50% w / w of the formulation.
[0056] For topical administration, the compositions of the present invention may be formulated as ointments, liquids, lotions, pastes, foams, sprays, serums, masks, gels, hydrogels or transdermal patches, leave-on and rinse-off lotions or toners, skin ampoules, skin cleansers, face and eye makeup removers, leave-on hair conditioners or hair vitamins, hair styling agents, shower gels / creams, bathroom bar soaps, antiperspirants, deodorants, depilatories, all color cosmetics including but not limited to lipsticks and foundations, sunless tanners or sunscreens, shampoos, conditioners, hair tonics, mousses, gels, liposomes or other forms suitable for topical use.
[0057] For example, ointments and creams can be formulated with a water base or an oil base, and appropriate thickeners, emulsifiers and / or gelling agents (e.g., oil-in-water emulsions, water-in-oil emulsions, or water-in-silicon emulsions) can be added. Emulsions can be formulated with a water base or an oil base, and generally also contain one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners, colorants, or preservatives (e.g., methylparaben, propylparaben, phenoxyethanol). Ointments, creams, lotions, etc. can also be formulated to contain C 1-3 Alkoxylated oils and waxes (eg ethoxylated vegetable oils, ethoxylated jojoba oil / wax, ethoxylated lanolin oil, ethoxylated coconut oil, ethoxylated cocoa butter).
[0058] In some embodiments, the composition may be formulated with one or more additional ingredients that are useful for treating skin disorders, such as hyaluronic acid and / or aloe vera gel.
[0059] The composition may also include a carrier and / or a vehicle to formulate the encapsulated boswellic acid and / or its derivatives into a suitable pharmaceutical or cosmetic formulation. The composition may also contain various known conventional additives, as long as they do not adversely affect the microbial balance provided by the encapsulated boswellic acid and / or its derivatives or the composition of the present invention. CTFA Cosmetic Ingredient Handbook, Second Edition, 1992 describes various non-limiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry that are suitable for the composition of the present invention. Examples of suitable formulation ingredients include: antioxidants, soothing or sedatives, moisturizing active substances, adhesives, biological additives, buffers, colorants or pigments, thickeners, polymers, astringents, fragrances, moisturizers, sunscreens, care agents, exfoliants, pH adjusters, preservatives, rheology modifiers, foaming agents, surfactants, emollients, natural extracts, essential oils, skin sensitizers, skin soothing agents and skin healing agents. The skin microbiome balancing activity of the composition comprising the formulation matrix may also include other skin conditioning agents, including but not limited to vitamins or vitamin derivatives and macrocapsules or microcapsules containing vitamins or their derivatives, cosmetic peptides, plant extracts, polyphenolic compounds, sunscreen additives, sunscreens, sensory additives or texture agents, natural extracts and essential oils. Exemplary preservatives include ethylhexylglycerin and phenoxyethanol. An exemplary moisturizer is 1,2-hexanediol.
[0060] In the case where the composition is in the form of a spray, the carrier is suitably water, and the composition may further comprise a preservative such as benzyl alcohol (e.g. in an amount of 0.1-5 wt%), a cosolvent such as propylene glycol (e.g. in an amount of 1-20 wt%) and a surfactant such as PEG-40 hydrogenated castor oil (e.g. in an amount of 1-20 wt%).
[0061] Where the composition is in the form of a lotion, it may further comprise water in the presence of a suitable emulsifier. Examples of suitable emulsifiers are cetyl alcohol-20, PEG-100 stearate, glyceryl stearate, sodium cetearyl sulfate. The composition may further comprise emollients and fragrances in the form of esters and / or hydrocarbons and / or silicones and / or vegetable oils, preservatives (e.g. benzyl alcohol at a level of 0.1-10%) and humectants and / or excipients (e.g. glycerol at a level of 0.5-10% and cyclomethicone at a level of 0.1-20%).
[0062] When the composition is in the form of an ointment, it may further comprise a conventional ointment base, to which the active ingredient is added. The ointment base may be a paraffin, such as soft paraffin, or a combination of soft paraffin and liquid paraffin. Other ointment bases may also be used, such as a polyalkylene glycol (such as polyethylene glycol or polypropylene glycol) base. Other possible ingredients of the ointment composition include emulsifying wax (e.g., in an amount between 1-40%, preferably 5-40%), and an optional preservative.
[0063] When the composition is in the form of a liquid soap, any known liquid soap may be used. The key ingredient of the preferred liquid soap, saponified fatty acids, is derived from palm kernel oil or coconut oil. The pH of the liquid soap base may be adjusted to a level suitable for surface use.
[0064] When the composition is an anhydrous cream, any suitable cream base may be used. Preferred cream bases are petrolatum creams and / or natural vegetable oils and waxes which introduce a consistency factor.
[0065] When the composition is a shampoo or a conditioner, in addition to the active ingredients, it may further comprise one or more of a surfactant, a thickener, a pH regulator / buffer, an aesthetic additive, water, a conditioning agent, a preservative, and a moisturizer / vitamin. Shampoo may also include other active ingredients known to those skilled in the art, which have some advantages in treating skin diseases such as psoriasis, eczema, dermatitis, or alopecia or other head or scalp diseases or conditions when included in the shampoo formulation or in a pharmaceutical combination. Shampoo may include a primary surfactant that provides a flash of foam to clean the hair by removing dirt and other impurities. A secondary surfactant may be included to provide a stable foam and reduce the irritation of the primary surfactant. A surfactant may be used that includes a charged hydrophilic head group and a long hydrophobic alkyl chain tail. The role of the surfactant is to reduce the surface tension of the phase between dirt and hair, so that the dirt is transported to the aqueous medium so that it can be rinsed off from the hair and scalp. According to certain embodiments, examples of surfactants that may be included in shampoos include sodium polyoxyethylene alkyl sulfate, ammonium lauryl sulfate, and sodium cocoyl isethionate. Examples of auxiliary surfactants include cocamide MEA and cocamidopropyl betaine. Suitable thickeners or suspending agents include carbomer and PEG 150 distearate. Thickeners may be included to stabilize the shampoo during storage and / or prevent precipitation or pouring of pigments and silicones. Suitable pH adjusters or buffers include citric acid, tartaric acid and sodium hydroxide. pH adjusters or buffers are formulated to make the shampoo mild to the skin. A lower pH can make the hair dense and shiny and protect the surfactant from hydrolysis, so the pH
[0066] method
[0067] In one aspect, the invention provides a composition as described above for use in treating subclinical symptoms of sensitive skin in a subject.
[0068] In another aspect, a method of treating subclinical symptoms of sensitive skin in a subject is provided, comprising applying the above composition to the subject's skin.
[0069] In another aspect, the present invention provides a use of the above composition in producing a medicament for treating subclinical symptoms of sensitive skin.
[0070] Subclinical symptoms of sensitive skin include impaired skin barrier function (which affects the outer surface of the skin, including the stratum corneum, the outermost layer of the epidermis) and increased skin nerve sensitivity. The prevalence of Staphylococcus epidermidis on the skin is linearly correlated with transepidermal water loss (TEWL), which is an indicator of impaired skin barrier function, and a higher lactic acid sting test (LAST) virtual analog score (VAS) is an indicator of skin nerve sensitivity. By normalizing the number of Staphylococcus epidermidis on the skin, the composition of the present invention can significantly reduce TEWL and VAS scores in people with sensitive skin. The microbiome normalization ability of the present invention can also be applied to skin and scalp problems with other microbiome spectrum disorders, including but not limited to acne skin or acne-prone skin, oily skin, dry skin, hair loss, hair graying, thinning hair, dandruff, sensitive scalp, irritated scalp and aging scalp, and works by preventing / inhibiting the growth of microorganisms, especially microorganisms that cause sensitive skin related to TEWL and LAST.
[0071] In some embodiments, the compositions of the present invention adjust the skin microbiome of a person with sensitive skin toward the microbiome of a person with healthy skin. In some embodiments, the compositions of the present invention normalize the skin microbiome of a person with sensitive skin to provide a skin microbiome of healthy skin.
[0072] As used herein, the phrases "microbiome balance" or "microbiome normalization" refer to the selective reduction of harmful microorganisms present on the skin while maintaining or increasing beneficial microorganisms.
[0073] Examples of bacteria whose growth may be reduced include, but are not limited to, bacteria of the phylum Firmicutes, which consists of more than 200 different genera, such as Streptococcus, Lactobacillus, Bacillus, Clostridium, Enterococcus, and Ruminicoccus. Examples of bacteria whose growth may be prevented or inhibited according to the present invention include, but are not limited to, Staphylococcus epidermidis, Staphylococcus capitis, Staphylococcus caprae, Staphylococcus aureus, Staphylococcus hominis, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus massiliensis, and Staphylococcus simulans, Streptococcus spp, Streptococcus mitis, Streptococcus oralis, Streptococcus infantis, and Streptococcus periodonticum.
[0074] In some embodiments, the methods and uses of the present invention are used to balance the skin microbiome to treat sensitive skin. In other embodiments, the microbiome normalization capabilities of the present invention can also be applied to skin or scalp problems with other microbiome spectrum disorders, including but not limited to acne skin or acne-prone skin, oily skin, dry skin, hair loss, thinning hair, dandruff, sensitive scalp, irritated scalp, hair loss, graying hair, pigmented skin, dandruff, atopic dermatitis or seborrheic dermatitis.
[0075] The composition is a topical composition that is applied to an external surface of a subject. In a specific embodiment, the external surface is the skin of a subject.
[0076] In general, the compositions of the present invention are topically applied at least once a day, preferably twice a day, for a period of time sufficient to provide the skin with a desired level of improvement, such as reduced skin sensitivity. Alternatively, these compositions can be applied once, twice, three times, or four times a week. For example, a user can topically apply the compositions of the present invention directly to the skin in need of reduced sensitivity by gently massaging the compositions of the present invention in the desired area. This process can be repeated later in the same day. In some embodiments, the compositions of the present invention are left on the skin in need of reduced sensitivity between applications performed on the same day.
[0077] Topical application of the compositions of the present invention may continue for any suitable period of time. For example, within a few days to a few weeks of initial application, the user may notice a reduction in skin sensitivity. It should be understood that the frequency of application of the compositions of the present invention will vary depending on the desired effect. In some embodiments, the degree of improvement in the therapeutic effect will vary with the total amount of the composition used.
[0078] When applied topically, the compositions of the present invention may be applied to the area to be treated, such as human skin, by spraying, spotting, wiping, rubbing or massaging.
[0079] In some embodiments, the composition is intended to be applied to a local area or surface of a body part, and is intended to produce a pharmacodynamic effect on the local area. The methods and uses of the present invention can improve the skin barrier function of a subject. Without wishing to be bound by theory, the improvement of skin barrier function can be mediated at the molecular level or by the involvement of protein biomarkers that have been shown in the art to be related to skin barrier function, including but not limited to: increased expression of filaggrin, involucrin, loricrin, and transglutaminase-1 in keratinocytes located in the stratum corneum of the epidermis, as well as increased claudin-1 and occludin, which play a tight junction role to control the permeability of molecules in the inner epidermis. The present invention can also improve the skin nerve sensitivity of a subject. Without wishing to be bound by theory, the improvement in skin neurosensitivity may be mediated at the molecular level through the involvement of protein biomarkers that have been shown in the art to be associated with neurosensitivity, including but not limited to: reduced secretion of nerve growth factor (NGF) that promotes the innervation of the epidermis, reduced release of neuropeptides from skin neurons, including substance P and calcitonin gene-related peptide (CGRP), inhibition of receptor activation of keratinocytes, including proteinase activated receptor 2 (PAR-2) and transient receptor potential vanilloid 1 (TRPV1), and reduced release of inflammatory mediators, including interleukin-8, interleukin-6, interleukin-1β, tumor necrosis factor α (TNF-α), thymic stromal lymphopoietin (TSLP), prostaglandin E2 that triggers skin reactions (stinging, itching or burning sensations) and / or skin neuroinflammation. The compositions of the present invention may also normalize the growth of other bacterial species involved in various skin conditions, including, but not limited to: Corynebacterium, Chryseobacterium, Snodgrassella spp., Coxsella, Micrococcus, and Lawsonella, which are known to be associated with sensitive skin in Caucasian populations; Corynebacterium and Enhydrobacter spp. and Prevotella spp., which are associated with skin aging; Staphylococcus aureus and Staphylococcus epidermidis, which are known to be associated with atopic dermatitis; Malassezia restricta and Malassezia globose, which are known to be associated with dandruff formation; Cutibacterium acne, which is known to be associated with acne skin; Corynebacterium kroppenstedtii, which is known to be associated with skin redness; and Corynebacterium, which is associated with hair loss and graying.
[0080] The "subject" may be a mammal. In a specific embodiment, the subject is a human.
[0081] In a particular embodiment, the methods and uses of the present invention are for treating sensitive skin, particularly sensitive skin of a subject that has been exposed to external factors including allergens, cosmetic ingredients, or extreme climatic conditions.
[0082] As used herein, "sensitive skin" refers to skin that is more prone to inflammation or adverse reactions. People with sensitive skin may have strong reactions to chemicals, dyes, and fragrances present in products that come into contact with the skin. Sensitive skin in human subjects may be caused by a higher abundance of harmful microorganisms from the Firmicutes phylum, such as Staphylococcus epidermidis. Without wishing to be bound by theory, it has been identified by next-generation sequencing analysis that Staphylococcus epidermidis is more abundant on sensitive skin. The abundance of this microorganism is also correlated with clinical parameters used to distinguish between healthy skin and sensitive skin, with the abundance of Staphylococcus epidermidis being linearly correlated with TEWL and LAST scores. Therefore, Staphylococcus epidermidis is considered a "sensitive skin-causing" microorganism, which is contrary to some studies that believe that Staphylococcus epidermidis is a skin-friendly microorganism.
[0083] In some embodiments, the compositions of the present invention improve overall skin health and reduce skin sensitivity by applying boswellic acids or derivatives thereof, optionally in the form of an extract of Boswellia serrata or in substantially pure form, to balance the skin microbiome and / or reduce sensitive skin by selectively reducing the dominant bacteria that cause sensitive skin, thereby maintaining high levels of beneficial microorganisms, such as microorganisms belonging to the phylum Proteobacteria, on the surface.
[0084] In some embodiments, microbiome balance is achieved by selectively reducing at least one microorganism selected from the genus Staphylococcus. In some embodiments, microbiome balance is achieved by selectively reducing the abundance of Staphylococcus epidermidis. Example
[0085] The present invention is further illustrated by the following experimental studies and examples, which should not be construed as limiting. The contents of all references, patents and published applications cited in this patent are hereby incorporated by reference.
[0086] Example 1: Evaluation of different skin microbiome profiles between sensitive skin and healthy skin
[0087] Methodology
[0088] Skin assessment and microbiological sampling
[0089] In this study, 24 women were divided into two groups: the sensitive skin group with a transepidermal water loss (TEWL) of more than 15 g m-2 h -1 The skin barrier function of the healthy skin group was impaired and the LAST score was greater than 2, which indicated increased nerve sensitivity. The healthy skin group was classified as having a TEWL less than 15 g m -2 h -1 The skin barrier function of the subjects was classified as normal and the nerve sensitivity of the subjects was classified as normal with a LAST score of less than 2. All group members were asked to use a standard facial cleanser for 3 consecutive days before skin assessment and microbial sampling. The skin barrier function of each subject was assessed by a TEWA meter TM300 (Courage+Khazaka electronicGmbH, Germany). In contrast, skin nerve sensitivity (tingling potential) was assessed using a lactic acid sting test, with a qualitative score of 0-4 based on the degree of tingling perception felt by the group members, and the results were interpreted as a visual analog score (VAS) of the initial, 2.5-minute and 5-minute tingling response after the application of 10% w / w lactic acid in the nasolabial area. In addition, skin microbial sampling of each group member was also performed at the same time, and total genomic DNA was extracted from the swab using a DNeasy PowerSoil DNA isolation kit (Qiagen, USA) according to the manufacturer's instructions.
[0090] Next-generation sequencing
[0091] The V3-V4 hypervariable region of the bacterial 16S rRNA gene was amplified by PCR using primers 341F (5'-CCTAYGGGRBGCASCAG-3') and 806R (5'-GGACTACNNGGGTATCTAAT-3'). The NEB NextUltra DNA Library was used according to the manufacturer's recommendations. Kit for Illumina generates sequencing libraries and adds index codes. Library quality was evaluated on Qubit@2.0Fluorometer (Thermo Scientific, USA) and Agilent Bioanalyzer 2100 systems. The library was then sequenced on the Illumina platform to generate 250bp paired-end reads. First, BBDuk (Bushnell, 2016) of the BBTools software package was used to remove the adapter sequences and low-quality reads of the paired-end reads. Afterwards, USEARCH v11.0.667 (Edgar & Flyvbjerg, 2015) was used to merge the forward and reverse reads. All sequences shorter than 150bp or longer than 600bp (sequencing on the MiSeq platform) were removed in downstream processing. The reads were then aligned to 16S rRNA (SILVA Release 132) and checked for chimera errors using VSEARCH v2.6.2 (Rognes, Flouri, Nichols, Quince, & Mahé, 2016). After these quality assessment steps, reads were clustered de novo into operational taxonomic units (OTUs) with 97% similarity using UPARSE v11.0.667 (Edgar, 2013); rare OUTs with less than 2 reads (doubleton) were usually spurious and removed from downstream processing. A representative sequence from each OTU was randomly selected and aligned to the SILVA 132 16S rRNA database using Pynast (Caporaso, Bittinger, et al., 2010) and a phylogenetic tree was constructed. The taxonomic assignment of OTUs was achieved using QIIME V1.9.1 against the Silva database 16S rRNA database (release 132) (Caporaso, Kuczynski, et al., 2010). OTU abundance information was normalized using the sequence number standard corresponding to the sample with the least sequence. Subsequent alpha diversity and beta diversity analyses were performed based on this output normalized data.
[0092] Next-generation sequencing analysis
[0093] Alpha diversity was used to analyze the complexity of the species diversity of the samples using six indices, including observed species, Chao1, Shannon, Simpson, ACE, and Good-coverage. All indices in the samples were calculated using QIIME (version 1.9.1) and displayed using R software (version 3.6.1). Beta diversity analysis was used to assess the differences in species complexity among the samples, and the beta diversity of weighted and unweighted unifracs was calculated using QIIME software (version 1.9.1). Cluster analysis was preceded by principal component analysis (PCA), and the dimensions of the original variables were reduced using the FactoMineR package and ggplot2 package (version 3.6.1) in R software. Principal coordinate analysis (PCoA) is used to obtain principal coordinates from complex multidimensional data and visualize them. The previously obtained weighted or unweighted unifrac distance matrix between samples was transformed into a new set of orthogonal axes, whereby the largest factor of variation was displayed by the first principal coordinate, the second largest factor of variation by the second principal coordinate, and so on. PCoA analysis was performed by the WGCNA package, stat package, and ggplot2 package in R software (version 3.6.1). The pairwise grouping method of unweighted arithmetic mean (UPGMA) clustering was performed as a hierarchical clustering method using the average linkage explanatory distance matrix and was performed by QIIME software (version 1.9.1). The linear discriminant analysis (LDA) effect size tool-LEfSe was used to identify OTUs with differences in relative abundance between normal skin, sensitive skin, and after treatment with SOS 1.1 (Segata et al., 2011). The LDA scores of OTUs with P ≤ 0.05 and LDA score threshold ≥ 2.00 were calculated.
[0094] Results and discussion
[0095] Different microbiome profiles of sensitive and healthy skin
[0096] As shown in Figure 1, more than 98% of the detected OUT counts belonged to the four major phyla of the skin microbiome, including Bacteoidates, Proteobacteria, Firmicutes, and Actinobacteria. Among these four major phyla, about 50% of the abundance in the healthy skin group and the sensitive skin group belonged to Actinobacteria. Compared with the healthy skin group, the abundance of bacteria belonging to the Firmicutes phylum was significantly higher in the sensitive skin, while the abundance of bacteria belonging to the Proteobacteria phylum was lower ( Figure 1A This finding is consistent with the study by Hillion et al. (2013), in which a lower proportion of Proteobacteria was found in the sensitive skin group. At the species level, the abundance of Staphylococcus epidermidis was significantly higher in the sensitive skin group compared to healthy skin ( Figure 1BThis observation is contrary to earlier studies that suggested that S. epidermidis is a skin-friendly bacterium that is favored for growth and skin dominance (WO2020052916 and WO2109086327).
[0097] Correlation between Staphylococcus epidermidis and clinical parameters of sensitive skin
[0098] The abundance of S. epidermidis was further analyzed in relation to clinical parameters related to the inclusion criteria used to distinguish healthy from sensitive skin. As shown in Table 1, the abundance of S. epidermidis was linearly correlated with TEWL and LAST scores. This observation further emphasizes the pathogenic role of S. epidermidis, which is associated with the development of sensitive skin with impaired skin barrier function (high TEWL) and increased cutaneous neurosensitivity (high LAST score). In summary, the skin dominance of S. epidermidis has been shown to play a key pathogenic role and is associated with the development of sensitive skin.
[0099] Table 1: Correlation between the abundance of Staphylococcus epidermidis and the clinical parameters of transepidermal water loss (TEWL) and lactic acid sting test (LAST) scores
[0100] No. parameter Relevance p-value 1 Transepidermal water loss (TEWL) Linear 0.0008 2 Visual Analogue Scale (VAS) of Lactic Acid Sting Test (LAST) Linear 0.0239
[0101] in conclusion
[0102] Differences in skin microbiome profiles between sensitive skin and healthy skin were identified. The sensitive skin group was found to have a relatively higher abundance of Firmicutes and a lower abundance of Proteobacteria at the phylum level. The sensitive skin group was found to have a relatively higher abundance of Staphylococcus epidermidis at the species level. Staphylococcus epidermidis was identified as a potential pathogenic bacterium occurring in sensitive skin, and its presence was positively correlated with TEWL and LAST, which are associated with impaired skin barrier function and increased neurosensitivity.
[0103] Example 2: Preparation of Compositions of Encapsulated Boswellic Acid Derivatives
[0104] Methodology
[0105] Preparation method
[0106] As shown in Table 2, the extract of Boswellia serrata is dissolved in an emollient such as C 12-15 In the alkyl benzoate, glyceryl citrate / lactate / linoleate / oleate and diglyceryl monooleate are dissolved in pentylene glycol. Then, the mixture is mixed until it is transparent and deionized water is added. Finally, the premix is processed for 2 cycles using a high pressure homogenizer (Microfluidizer) at a pressure of 700 bar.
[0107] Table 2: Composition of encapsulated boswellic acid derivatives
[0108]
[0109] Particle size identification
[0110] The average surface charge and size distribution were determined by dynamic light scattering using a Zetasizer ZS Nano (Malvern Instruments, Worcestershire, UK). The composition contained nanoemulsions, wherein each nanoemulsion had a size in the range of 60-180 nm and a surface charge of -65 to -75 mV. A cartoon representation of the nanoemulsion encapsulating the boswellic acid derivative is shown in Figure 2 shown.
[0111] Example 3: Preparation of Compositions Containing Encapsulated Boswellic Acid Derivatives
[0112] Methodology
[0113] Composition preparation
[0114] Premix A (aqueous phase) and premix B (lipid phase) were prepared separately and each phase was mixed until completely dissolved. Premix B was then added to premix A and homogenized at 2500 rpm for 15 minutes. Premix C was prepared as described in Example 2 and added to the mixture of premix A and premix B, and the composition was homogenized at 2500 rpm for 5 minutes and stirred at 100-200 rpm for 10 minutes. The composition of premix A, B and C is shown in Table 3.
[0115] Table 3
[0116]
[0117]
[0118] Activity analysis of boswellic acid derivatives
[0119] Ultra-performance liquid chromatography (UPLC, from Waters, USA) was used to quantify the level of 3-O-acetyl-11-keto-boswellic acid (AKBA) in the preparation. In brief, AKBA was extracted from the sample using 100% methanol (Merck, Germany) with the assistance of an ultrasonic generator at 37kHz. The extract solution was filtered into a UPLC amber vial through a 0.22μm polytetrafluoroethylene (PTFE) membrane (Agilent, USA) and then subjected to UPLC analysis. The UPLC system was equipped with a photodiode array detector (PDA) and a C18 Chromolith RP-18e octadecylsilane (ODS) separation column (Merck. Germany), with a mobile phase of 0.5% (w / w) acetic acid and 100% (w / w) acetonitrile in a mixing ratio of 1:10, and the entire analysis process was performed in isocratic elution mode with a flow rate of 1.00mL / min. Finally, the AKBA peak was determined at a retention time of 4.39 ± 0.04 min and an absorbance wavelength of 254 nm. External calibration was used for the quantification of AKBA, with the calibration standard ranging from 10 μg / mL to 150 μg / mL.
[0120] The stability of the compositions comprising encapsulated boswellic acid derivatives was evaluated by analyzing the level (%) of AKBA in the compositions and by visual inspection before and after storage at 45°C for 3 months.
[0121] Results and discussion
[0122] As shown in Table 4, at an accelerated temperature of 45°C for 3 months, both compositions with different dosages of encapsulated boswellic acid derivatives showed excellent stability, including the physical appearance and chemical stability of 3-O-acetyl-11-keto-boswellic acid (AKBA).
[0123] Table 4: Product stability of compositions comprising encapsulated boswellic acid derivatives
[0124]
[0125] in conclusion
[0126] The composition comprising the encapsulated boswellic acid derivatives exhibited good physical stability at elevated temperature (45°C) for 3 months. In addition, the encapsulated boswellic acid derivatives exhibited excellent chemical stability at accelerated temperature (45°C) for 3 months.
[0127] Example 4: Effect of a composition comprising encapsulated boswellic acid derivatives on the skin microbiome profile and mitigation of sensitive skin Clinical assessment of subclinical symptoms
[0128] Purpose
[0129] The product efficacy of the selected formula 1 on the skin barrier function, neurosensitivity and skin microbiome profile of members of the sensitive skin group and the healthy skin group was evaluated.
[0130] Methodology
[0131] Composition preparation
[0132] The composition was prepared as described in Example 3.
[0133] Clinical Research
[0134] Briefly, 24 women were subdivided into 2 groups, sensitive skin group and healthy skin group (as defined in the Methodology section of Example 1). All panelists were instructed to use standard facial cleansing products for 3 consecutive days before baseline measurements of skin assessment and microbial sampling. Then, the panelists were instructed to use Formula 1 twice a day on the facial area for 4 weeks. Finally, skin parameters such as skin barrier function, skin nerve sensitivity and microbial sampling were evaluated according to the protocol described in the Methodology section of Example 1. The effects of the product on changes in skin condition and microbiome profiles in both sensitive skin and healthy skin groups.
[0135] Results and discussion
[0136] like Figure 3 As shown, in the sensitive skin group, product treatment with Formula 1 significantly improved skin nerve sensitivity by reducing VAS scores and improved skin barrier function by showing a reduction in TEWL (P value = 0.1328). In contrast, in the healthy skin group, no significant changes were found in these two clinical parameters with Formula 1 treatment. Correlation with microbiome profile ( Figure 4 ), Formula 1 significantly normalized the abundance of bacteria belonging to the Firmicutes phylum, more specifically Staphylococcus epidermidis, in the sensitive skin group and brought the microbiome profile closer to the condition of healthy skin. In addition, in the healthy skin group, no significant changes in the microbiome profile were found after Formula 1 treatment.
[0137] in conclusion
[0138] Formula 1, containing encapsulated boswellic acid derivatives, improved cutaneous neurosensitivity and skin barrier function in members of the sensitive skin group, while bringing the skin microbiome profile closer to that of healthy skin.
[0139] Formula 1 comprising encapsulated boswellic acid derivatives normalized the abundance of bacteria belonging to the phylum Firmicutes, more specifically Staphylococcus epidermidis, in members of the sensitive skin group.
[0140] Formula 1 containing the encapsulated boswellic acid derivative did not disrupt the skin microbiome profile of healthy skin group members.
[0141] References:
[0142] Alekseyenko,A.V.,Perez-Perez,G.I.,De Souza,A.et al.Communitydifferentiation of the cutaneous microbiota in psoriasis.Microbiome 1,31(2013).
[0143] Berardesca,E.,Farage,M.&Maibach,H.Sensitive skin:Anoverview.Int.J.Cosmet.Sci.35,2–8(2013).
[0144] Byrd AL,Deming C,Cassidy SKB,et al.Staphylococcus aureus andStaphylococcus epidermidis strain diversity underlying pediatric atopicdermatitis.Sci Transl Med.2017;9(397):eaal4651.
[0145] Calzavara-Pinton,P.,Zane,C.,Facchinetti,E.,Capezzera,R.,Pedretti,A.Topical Boswellic acids for treatment of photoaged skin.Dermatol Ther.2010;23Suppl 1:S28-S32.
[0146] Raja AF,Ali F,Khan IA,et al.Antistaphylococcal and biofilm inhibitoryactivities of acetyl-11-keto-β-boswellic acid from Boswellia serrata.BMCMicrobiol.2011;11:54.
[0147] Shinohara,K.,Masaki,H.The role of resident microbiome in the onset ofskin sensitivity.IFSCC Proceeding(2019)
[0148] Siddiqui,M.Z.Boswellia serrata,a potential antiinflammatory agent:anoverview.Indian J Pharm Sci.2011;73(3):255-261.
[0149] Togni,S,Maramaldi,G.,Di Pierro,F.,Biondi,M.A cosmeceuticalformulation based on boswellic acids for the treatment of erythematous eczemaand psoriasis.Clin Cosmet Investig Dermatol.2014;7:321-327.
[0150] Bushnell,B.(2016).BBtools. https: / / doi.org / 10.1371 / journal.pone.0185056
[0151] Caporaso,J.G.,Bittinger,K.,Bushman,F.D.,Desantis,T.Z.,Andersen,G.L.,&Knight,R.(2010).PyNAST:A flexible tool for aligning sequences to a templatealignment.Bioinformatics.https: / / doi.org / 10.1093 / bioinformatics / btp636
[0152] Caporaso,J.G.,Kuczynski,J.,Stombaugh,J.,Bittinger,K.,Bushman,F.D.,Costello,E.K.,…Knight,R.(2010).QIIME allows analysis of high-throughputcommunity sequencing data.Nature Methods.https: / / doi.org / 10.1038 / nmeth.f.303
[0153] Edgar,R.C.(2013).UPARSE:Highly accurate OTU sequences from microbialamplicon reads.Nature Methods.https: / / doi.org / 10.1038 / nmeth.2604
[0154] Edgar,R.C.,&Flyvbjerg,H.(2015).Error filtering,pair assembly anderror correction for next-generation sequencing reads.Bioinformatics.https: / / doi.org / 10.1093 / bioinformatics / btv401
[0155] Hillion M,Mijouin L,Jaouen T,et al.(2013).Comparative study of normaland sensitive skin aerobic bacterial populations.Microbiologyopen.2(6):953-961.doi:10.1002 / mbo3.138
[0156] Rognes,T.,Flouri,T.,Nichols,B.,Quince,C.,&Mahé,F.(2016).VSEARCH:Aversatile open source tool for metagenomics.PeerJ.https: / / doi.org / 10.7717 / peerj.2584
[0157] Segata,N.,Izard,J.,Waldron,L.,Gevers,D.,Miropolsky,L.,Garrett,W.S.,&Huttenhower,C.(2011).Metagenomic biomarker discovery and explanation.GenomeBiology.https: / / doi.org / 10.1186 / gb-2011-12-6-r60
[0158] Umair Shamraiz,Hidayat Hussain,Najeeb Ur Rehman,Sulaiman Al-Shidhani,Aasim Saeed,Husain Yar Khan,Ajmal Khan Lucie Fischer,RenéCsuk,Amin Badshah,Ahmed Al-Rawahi,Javid Hussain&Ahmed Al-Harrasi(2018)Synthesis of newboswellic acid derivatives as potential antiproliferative agents,Nat.Prod.Res.2018,(34)pp1845-1852。
Claims
1. A topical composition comprising boswellic acid, one or more boswellic acid derivatives or a mixture thereof, wherein the boswellic acid, the boswellic acid derivatives or the mixture thereof are encapsulated in a nanoemulsion having a liquid lipid core and a negative surface charge of -50 to -90 mV, wherein the nanoemulsion further comprises at least one emulsifier, a co-emulsifier, a stabilizer and at least one emollient, wherein the emollient comprises C 12-15 Alkyl benzoate, wherein the one or more boswellic acid derivatives are selected from the group consisting of α-boswellic acid, acetyl-α-boswellic acid, β-boswellic acid (BBA), acetyl-β-boswellic acid (ABA), 9,11-dehydro-α-boswellic acid, acetyl-9,11-dehydro-α-boswellic acid, 9,11-dehydro-β-boswellic acid, acetyl-9,11-dehydro-β-boswellic acid, lupeolic acid, acetyl-lupeolic acid, 11-keto-β-boswellic acid (KBBA) and 3-O-acetyl-11-keto-β-boswellic acid (AKBA), wherein the at least one emulsifier comprises glycerol citrate, glycerol lactate, glycerol linoleate and / or glycerol oleate, the co-emulsifier is diglycerol monooleate, and the stabilizer is pentylene glycol.
2. The external composition according to claim 1, wherein the size of each nanoemulsion is in the range of 50-200 nm.
3. A topical composition according to claim 1 or 2, wherein the boswellic acid, one or more boswellic acid derivatives or a mixture thereof is present in an amount of 0.001% to 2.0% by weight of the composition.
4. The external composition according to claim 1 or 2, wherein the boswellic acid, one or more boswellic acid derivatives or a mixture thereof comprises 3-O-acetyl-11-keto-β-boswellic acid (AKBA).
5. The external composition according to claim 1 or 2, wherein the boswellic acid, one or more boswellic acid derivatives or a mixture thereof is obtained from a plant extract or is contained in a plant extract.
6. The external composition according to claim 5, wherein the plant extract is an extract of Boswellia serrata.
7. The external composition according to claim 6, wherein the composition comprises an extract of Boswellia serrata.
8. The topical composition according to claim 1 or 2, further comprising one or more ingredients selected from the group consisting of vitamin polyphenol compounds, preservatives, humectants, rheology modifiers, surfactants, foaming agents, sunscreens, sensory additives or texturizers, pigments, natural extracts, essential oils, large or small capsules containing vitamins, peptides, plant extracts, sunscreens and essential oils.
9. The topical composition according to claim 1 or 2, wherein the composition is formulated as a leave-on toner, skin serum, skin ampoule, skin lotion or cream, skin cleanser, facial and eye makeup remover, shampoo, conditioner, hair tonic, hair styling aid, shower gel or shower cream, bathroom bar soap, antiperspirant, deodorant, depilatory, all color cosmetics not limited to lipstick and foundation, sunless tanner or sunscreen.
10. Use of a topical composition according to any one of claims 1 to 9 for the manufacture of a medicament for normalizing the skin microbiome profile of a subject with sensitive skin.
11. Use according to claim 10, wherein normalizing the skin microbiome profile reduces the abundance of bacterial species belonging to the phylum Firmicutes.
12. Use according to claim 11, wherein the bacterial species is selected from Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus hominis or Staphylococcus capitis.
